search
Back to results

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Primary Purpose

Dravet Syndrome

Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Cannabidiol Oral Solution
Placebo Solution
Sponsored by
INSYS Therapeutics Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dravet Syndrome focused on measuring Treatment-resistant seizures

Eligibility Criteria

1 Year - 30 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Meets protocol-specified criteria for qualification and contraception, including clinical diagnosis of refractory DS and onset of seizures according to protocol-specified criteria
  • Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure
  • In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able to keep accurate seizure diaries and the participant is able to take study drug and comply with the protocol, including dosing, medications and diet

Exclusion Criteria:

  • Medical history is outside protocol-specified parameters
  • Clinically significant history of allergic reactions or significant sensitivities to cannabinoids or to any of the other ingredients in the study drug
  • Inadequate supervision by parents or guardians
  • History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters
  • Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Cannabidiol Oral Solution

    Placebo Solution

    Arm Description

    Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.

    Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.

    Outcomes

    Primary Outcome Measures

    Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components

    Secondary Outcome Measures

    Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components
    Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components
    Percent change from baseline in the frequency of all seizure activity independent of seizure type
    Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Improvement (CGI-I)
    Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Severity (CGI-S)
    Change from baseline in Investigator CGI-I
    Change from baseline in Investigator CGI-S

    Full Information

    First Posted
    December 12, 2014
    Last Updated
    January 2, 2018
    Sponsor
    INSYS Therapeutics Inc
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02318563
    Brief Title
    Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
    Official Title
    A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2018
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Sponsor elected not to continue with study.
    Study Start Date
    December 30, 2017 (Anticipated)
    Primary Completion Date
    June 17, 2018 (Anticipated)
    Study Completion Date
    June 17, 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    INSYS Therapeutics Inc

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This Phase 3 study will enroll participants diagnosed with Dravet Syndrome (DS) who are still experiencing at least one tonic-clonic, clonic, and/or focal seizures with motor components (FSMC) per week, despite ongoing treatment with up to three antiepileptic drugs (AEDs), and meet the other inclusion/exclusion criteria. Following a 28-day baseline period, participants will begin an 84-day treatment period. Participants will be assigned to receive twice-daily doses of placebo or cannabidiol oral solution at the highest dose determined to be safe in a previous trial. Following study completion, all participants will be invited to receive Cannabidiol Oral Solution in an open label extension study (under a separate protocol).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Dravet Syndrome
    Keywords
    Treatment-resistant seizures

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Cannabidiol Oral Solution
    Arm Type
    Experimental
    Arm Description
    Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
    Arm Title
    Placebo Solution
    Arm Type
    Placebo Comparator
    Arm Description
    Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
    Intervention Type
    Drug
    Intervention Name(s)
    Cannabidiol Oral Solution
    Intervention Description
    An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo Solution
    Intervention Description
    A matching oral solution containing no cannabidiol
    Primary Outcome Measure Information:
    Title
    Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12
    Secondary Outcome Measure Information:
    Title
    Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12
    Title
    Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12
    Title
    Percent change from baseline in the frequency of all seizure activity independent of seizure type
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12
    Title
    Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Improvement (CGI-I)
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12
    Title
    Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Severity (CGI-S)
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12
    Title
    Change from baseline in Investigator CGI-I
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12
    Title
    Change from baseline in Investigator CGI-S
    Time Frame
    Data point for observation period to data point for treatment period Weeks 9 through 12

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    1 Year
    Maximum Age & Unit of Time
    30 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Meets protocol-specified criteria for qualification and contraception, including clinical diagnosis of refractory DS and onset of seizures according to protocol-specified criteria Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able to keep accurate seizure diaries and the participant is able to take study drug and comply with the protocol, including dosing, medications and diet Exclusion Criteria: Medical history is outside protocol-specified parameters Clinically significant history of allergic reactions or significant sensitivities to cannabinoids or to any of the other ingredients in the study drug Inadequate supervision by parents or guardians History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Neha Parikh
    Organizational Affiliation
    INSYS Therapeutics Inc
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

    We'll reach out to this number within 24 hrs